Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

Y Ohe1 Y Ohashi2 K Kubota3 T Tamura1 K Nakagawa4 S Negoro5 Y Nishiwaki3 N Saijo3 Y Ariyoshi6 and M Fukuoka4

首页> 外文期刊>Annals of Oncology >Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

【24h】

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

机译：顺铂加伊立替康与卡铂加紫杉醇，顺铂加吉西他滨，顺铂加长春瑞滨对晚期非小细胞肺癌的随机III期研究：日本的四臂合作研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: To compare the efficacy and toxicity of three platinum-based combination regimens against cisplatin plus irinotecan (IP) in patients with untreated advanced non-small-cell lung cancer (NSCLC) by a non-inferiority design.

机译：背景：通过非劣效性设计，比较三种铂类联合方案对顺铂加伊立替康（IP）治疗未治疗的晚期非小细胞肺癌（NSCLC）患者的疗效和毒性。

著录项

来源
《Annals of Oncology》 |2007年第2期|317-323|共7页
作者
Y Ohe1 Y Ohashi2 K Kubota3 T Tamura1 K Nakagawa4 S Negoro5 Y Nishiwaki3 N Saijo3 Y Ariyoshi6 and M Fukuoka4;
展开▼
作者单位

Department of Internal Medicine National Cancer Center Hospital Tokyo;

Department of Biostatistics/Epidemiology and Preventive Health Sciences School of Health Sciences and Nursing The University of Tokyo Tokyo;

Thoracic Oncology Division National Cancer Center Hospital East Kashiwa Chiba;

Department of Medical Oncology Kinki University School of Medicine Osakasayama Osaka;

Department of Thoracic Oncology Hyogo Medical Center for Adults Akashi Hyogo;

Aichi Cancer Center Aichi Hospital Okazaki Aichi Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. [J] . Ohe Y, Ohashi Y, Kubota K, Annals of oncology: official journal of the European Society for Medical Oncology . 2007,第2期

机译：顺铂加伊立替康与卡铂加紫杉醇，顺铂加吉西他滨，顺铂加长春瑞滨对晚期非小细胞肺癌的随机III期研究：日本的四臂合作研究。
2. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Onco [J] . Comella P, Frasci G, Panza N, Journal of Clinical Oncology . 2000,第7期

机译：比较顺铂，吉西他滨和长春瑞滨与顺铂和吉西他滨或顺铂和长春瑞滨在晚期非小细胞肺癌中的随机对照试验：意大利南部合作公司Onco的III期临床试验的中期分析
3. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. [J] . Laack E, Dickgreber N, Muller T, Journal of Clinical Oncology . 2004,第12期

机译：吉西他滨和长春瑞滨与吉西他滨，长春瑞滨和顺铂治疗晚期非小细胞肺癌的随机III期研究：来自德国和瑞士肺癌研究组。
4. Gemcitabine + Cisplatin Combination Electrochemotherapy for Triple Negative Breast Cancers: An in vitro Model Study [C] . R. Sundararajan, V. Raman, V. Masterson World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food Environmental Technologies . 2016

机译：Gemcitabine +顺铂组合电化学疗法三重阴性乳腺癌：体外模型研究
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP). [O] . E. Baldini, C. Tibaldi, A. Ardizzoni, 1998

机译：晚期非小细胞肺癌（NSCLC）患者的顺铂-长春地霉素-丝裂霉素（MVP）与顺铂-异环磷酰胺-长春瑞滨（PIN）与卡铂-长春瑞滨（CaN）：一项FONICAP随机II期研究。意大利肺癌工作组（FONICAP）。
7. C3-03: Randomized, phase III Study of mitomycin/vindesine/cisplatin (MVP) versus weekly irinotecan/carboplatin (IC) or weekly paclitaxel/carboplatin (PC) with concurrent thoracic radiotherapy (TRT) for unresectable stage III non-small-cell lung cancer (NSCLC): WJTOG0105 [O] . Yoshida Kimihide, Uejima Hisao, Satouchi Miyako, 2007

机译：C3-03：丝裂霉素/长春地辛/顺铂（MVP）与每周依立替康/卡铂（IC）或每周紫杉醇/卡铂（PC）联合胸腔放疗（TRT）进行不可切除的III期非小细胞III期随机研究肺癌（NSCLC）：WJTOG0105

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

摘要

著录项

相似文献

相关主题

期刊订阅